NIH-funded research R01 grant

How arsenic exposure causes cancer

Official title: Mechanism for arsenic induced carcinogenesis

Funded at University of Louisville · NIH-11467959 · Data updated 2026-11-12

Researchers are looking at how low-level arsenic exposure changes small RNAs and gene splicing in skin cells to explain why some people develop arsenic-related skin cancer.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of Louisville
NIH-funded
Lab location1 site (Louisville, United States)
Project startAugust 1, 2017
Project endNovember 30, 2028
Funding year2026
Award (this year)$142,558
NIH project number3R01ES027778-08S1
Project IDNIH-11467959 on NIH RePORTER

Who could benefit from this research

Could help

People with chronic arsenic exposure, arsenic-related skin lesions, or arsenic-associated squamous cell carcinoma would be most relevant for this research.

Less likely to help

People without a history of arsenic exposure or those with cancers unrelated to arsenic are unlikely to benefit directly from this work.

What this research studies

This project looks at how arsenic exposure alters microRNAs and the splicing of a related gene in human skin cells and how those changes lead to chromosomal instability. Scientists use human keratinocyte cell models (including a new Ker-CT model) and detailed karyotype analysis to track aneuploidy and other genetic changes. The team focuses on miR-186 and five other microRNAs that are overexpressed after arsenic exposure and may suppress mitotic regulators. Findings aim to map the molecular steps from arsenic exposure to tumor development to inform future detection or prevention efforts.

Why it matters

Potential benefit: If successful, this work could identify molecular markers or targets for earlier detection, prevention, or future treatments of arsenic-related skin cancers.

How similar studies have gone: Previous studies have linked arsenic exposure to miRNA changes and chromosomal instability, but using this new human keratinocyte model to map specific microRNAs like miR-186 is a relatively novel and exploratory approach.

Where this research is happening

  • University of Louisville
    Louisville, United States
    Active

Researchers

  • Principal investigator: States, J Christopher — University of Louisville
  • Study coordinator: States, J Christopher

Related research

Other NIH-funded projects on the same topics.

  • Gastric rhythm map to understand stomach problems using a new noninvasive tool

    A new noninvasive body surface mapping method is being tested to see if abnormal stomach electrical rhythms explain chronic stomach problems like functional dyspepsia and persistent nausea.

    NIH research University of Louisville · Louisville, United States · NIH-11611507

  • Novel antivirals for alphavirus arthritis

    A research team is refining a promising antiviral compound to treat alphavirus infections that cause arthritis, with a focus on Chikungunya and related viruses.

    NIH research University of Louisville · Louisville, United States · NIH-11609180

  • Linking heavy metal exposure to a tougher breast cancer type (TNBC)

    Aimed at understanding how heavy metals like cadmium might trigger a dangerous breast cancer type (TNBC) in people, especially those with BRCA1 risk, to identify possible future treatment strategies.

    NIH research University of Louisville · Louisville, United States · NIH-11567535

  • Cardiac safety of flavored e-cigarette aerosols in adults

    A pharmacist or clinician would test how inhaling flavored e-cigarette aerosols affects heart rhythm in adults to see if flavors raise the risk of heart problems.

    NIH research University of Louisville · Louisville, United States · NIH-11541950

  • Biomedical Research Facilities to Expand Precision Medicine in Kentucky

    A large NIH grant aims to renovate and expand a shared precision medicine center in Kentucky to speed up research that could improve health for people in Appalachia and surrounding areas.

    NIH research University of Louisville · Louisville, United States · NIH-11523167

  • Rac-enhanced CAR-Macrophages against TNBC

    A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.

    NIH research University of Louisville · Louisville, United States · NIH-11520503

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.